FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158436306> ?p ?o ?g. }

• W3158436306 endingPage "100386" @default.
• W3158436306 startingPage "100386" @default.
• W3158436306 abstract "More than 82,000 pregnant women in the United States have tested positive for SARS-CoV-2.1Centers for Disease Control and PreventionCOVID data tracker.2020https://covid.cdc.gov/covid-data-tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fcases-in-us.htmlDate accessed: December 28, 2020Google Scholar Published estimates of the incidence of vertical transmission—the passage of SARS-CoV-2 from the mother to her infant during pregnancy or childbirth—range from 1% to 3%, but these reports may be limited in their methodology.2Kotlyar AM Grechukhina O Chen A et al.Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis.Am J Obstet Gynecol. 2021; 224 (35–53.e3)Google Scholar, 3Flaherman VJ Afshar Y Boscardin WJ et al.Infant outcomes following maternal infection with SARS-CoV-2: first report from the PRIORITY study.Clin Infect Dis. 2020; ([Epub ahead of print])Crossref PubMed Scopus (29) Google Scholar, 4Woodworth KR Olsen EO Neelam V et al.Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020.MMWR Morb Mortal Wkly Rep. 2020; 69: 1635-1640Crossref PubMed Scopus (0) Google Scholar To date, the largest systematic review and meta-analysis reports a pooled estimate of 3.2%2Kotlyar AM Grechukhina O Chen A et al.Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis.Am J Obstet Gynecol. 2021; 224 (35–53.e3)Google Scholar and includes data from cohort studies and case series published early in the pandemic, when reports on outcomes of newborns with SARS-CoV-2 infection were urgently needed to guide clinical management and potentially overrepresented. Here, we provided additional data on vertical transmission from a multicenter cohort of pregnant women with SARS-CoV-2 infection. Women with a positive nasopharyngeal polymerase chain reaction (PCR) for SARS-CoV-2 during pregnancy who delivered from March 22, 2020, to December 20, 2020, at 1 of 3 hospitals in Boston, MA—Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH), and Beth Israel Deaconess Medical Center (BIDMC)—were included. These hospitals perform approximately 15,000 deliveries per year, accounting for approximately 75% of annual deliveries in Boston. The Mass General Brigham and BIDMC Institutional Review Boards approved this study. Some of the participants included in this study of vertical transmission have been included in previous studies describing different outcomes. Inpatient universal testing protocols for SARS-CoV-2 were in place in early April 2020 (MGH or BWH) or May 2020 (BIDMC). Outpatient testing was performed by clinical indication, that is, a known exposure or symptoms. Consistent with the American Academy of Pediatrics (AAP) guidelines released on April 2, 2020,5The American Academy of PediatricsFAQs: management of infants born to mothers with suspected or confirmed COVID-19.2020https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/faqs-management-of-infants-born-to-covid-19-mothers/Date accessed: January 15, 2021Google Scholar neonatal testing by nasopharyngeal PCR was performed at 24 hours of life only in newborns of mothers with SARS-CoV-2 infection who were considered infectious at the time of delivery and at 48 hours or later at the discretion of the provider or infection control. There was no case of SARS-CoV-2 infection identified in 369 newborns born to 354 women who tested positive for SARS-CoV-2 during pregnancy. Of the 369 delivered newborns, 159 newborns (43%) were tested at least once for SARS-CoV-2 during the delivery hospitalization, with 149 newborns (94%) receiving a test at 24 hours of life. Of the 354 women infected with SARS-CoV-2 during pregnancy included in this cohort, 140 (40%) delivered within 14 days from diagnosis of SARS-CoV-2 infection. The median interval from maternal diagnosis of SARS-CoV-2 infection to delivery was 29 days (interquartile range, 2–108). Asymptomatic or mild disease was noted in 259 women (73%). The Table depicts maternal and neonatal characteristics.TableCharacteristics of pregnant women testing positive for SARS-CoV-2 and frequency of newborn SARS-CoV-2 testingCharacteristicAll (N=354)MGH (n=144)BWH (n=130)BIDMC (n=80)Maternal disease severityaDefined by the National Institute of Health and endorsed by the Society for Maternal-Fetal MedicineAsymptomatic66 (19)31 (22)22 (17)13 (16)Mild192 (54)76 (53)75 (58)41 (51)Moderate59 (17)22 (15)23 (18)14 (18)Severe25 (7)11 (8)7 (5)7 (8)Critical12 (3)4 (3)3 (2)5 (6)GA at diagnosis in completed weeks32 (22–38)32 (23–38)33 (23–37)32 (19–36)GA at diagnosis by trimesterFirst37 (10)12 (8)16 (12)9 (11)Second92 (26)38 (26)29 (22)25 (31)Third225 (64)94 (65)85 (65)46 (58)GA at delivery in completed weeks39 (37–39)39 (38–39)39 (37–39)38 (37–39)Mode of deliveryVaginal delivery221 (62)89 (62)83 (64)49 (61)Cesarean delivery133 (38)55 (38)47 (36)31 (39)Preterm birth (<37 wk)bIncludes both iatrogenic and spontaneous preterm births53 (15)18 (13)18 (14)17 (21)Days from first positive test to delivery29 (2–108)33 (2–101)27 (2–106)26 (3–113)Women delivering <14 d from date of diagnosis140 (40)56 (39)49 (38)33 (41)Total newborns, n36915013584Positive for SARS-CoV-2cBy clinically available nasopharyngeal polymerase chain reaction for SARS-CoV-20 (0)0 (0)0 (0)0 (0)Negative for SARS-CoV-2cBy clinically available nasopharyngeal polymerase chain reaction for SARS-CoV-2159 (43)69 (46)60 (44)30 (36)Not tested for SARS-CoV-2cBy clinically available nasopharyngeal polymerase chain reaction for SARS-CoV-2210 (57)81(54)75 (56)54 (64)Incidence of vertical transmission, % (95% CI)dNumber of newborns testing positive for SARS-CoV-2 divided by number of newborns delivered to women with SARS-CoV-2 infection (all hospitals, 369; MGH, 150; BWH, 135; BIDMC, 84). The 95% CI was calculated using the exact (Clopper-Pearson) method.0 (0.0–1.0)0 (0.0–2.4)0 (0.0–2.7)0 (0.0–4.3)Newborns tested for SARS-CoV-2cBy clinically available nasopharyngeal polymerase chain reaction for SARS-CoV-2 after birth, n159696030Tested at 24 h only105 (66)49 (71)38 (63)18 (60)Tested at 24 h and 48 h–72 h31 (20)15 (22)4 (7)12 (40)Tested at 24 h and 4 d–14 d13 (8)4 (6)9 (15)0 (0)Tested at other time points10 (6)1 (1)9 (15)0 (0)Data are presented as number (percentage) or median (interquartile range), unless otherwise indicated.BIDMC, Beth Israel Deaconess Medical Center; BWH, Brigham and Women's Hospital; CI, confidence interval; GA, gestational age; MGH, Massachusetts General Hospital.Shook. Vertical transmission of SARS-CoV-2. Am J Obstet Gynecol MFM 2021.a Defined by the National Institute of Health and endorsed by the Society for Maternal-Fetal Medicineb Includes both iatrogenic and spontaneous preterm birthsc By clinically available nasopharyngeal polymerase chain reaction for SARS-CoV-2d Number of newborns testing positive for SARS-CoV-2 divided by number of newborns delivered to women with SARS-CoV-2 infection (all hospitals, 369; MGH, 150; BWH, 135; BIDMC, 84). The 95% CI was calculated using the exact (Clopper-Pearson) method. Open table in a new tab Data are presented as number (percentage) or median (interquartile range), unless otherwise indicated. BIDMC, Beth Israel Deaconess Medical Center; BWH, Brigham and Women's Hospital; CI, confidence interval; GA, gestational age; MGH, Massachusetts General Hospital. Shook. Vertical transmission of SARS-CoV-2. Am J Obstet Gynecol MFM 2021. We identified no case of vertical transmission in our cohort, which includes a large proportion of women with asymptomatic or mild disease. Newborns were tested per hospital infection control policies (eg, not tested if born to convalescent mothers). Although vertical transmission does occur, data from our centers suggest that the incidence of SARS-CoV-2 vertical transmission, as detected via neonatal nasopharyngeal swab, is likely lower than the 1% to 3% estimated incidence in previous reports.2Kotlyar AM Grechukhina O Chen A et al.Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis.Am J Obstet Gynecol. 2021; 224 (35–53.e3)Google Scholar, 3Flaherman VJ Afshar Y Boscardin WJ et al.Infant outcomes following maternal infection with SARS-CoV-2: first report from the PRIORITY study.Clin Infect Dis. 2020; ([Epub ahead of print])Crossref PubMed Scopus (29) Google Scholar, 4Woodworth KR Olsen EO Neelam V et al.Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020.MMWR Morb Mortal Wkly Rep. 2020; 69: 1635-1640Crossref PubMed Scopus (0) Google Scholar The challenge in selecting the denominator for calculating the incidence of vertical transmission is illustrated by the Centers for Disease Control and Prevention (CDC) report on 2869 newborns of women with SARS-CoV-2 infection during pregnancy.4Woodworth KR Olsen EO Neelam V et al.Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020.MMWR Morb Mortal Wkly Rep. 2020; 69: 1635-1640Crossref PubMed Scopus (0) Google Scholar Test results were available on 610 newborns—only 21% of the cohort—of which 16 (2.6%) tested positive for SARS-CoV-2. More than 60% of newborns without testing information were delivered >10 days from maternal infection. These newborns either were not tested or had a negative result, which is not mandated to be reported to the state, unlike a positive result. If all newborns born to women with SARS-CoV-2 infection during pregnancy were included in the denominator, the incidence of identified vertical transmission would be 0.6% (16 of 2869), not 2.6%. Consensus on how to define, detect, and report vertical transmission of SARS-CoV-2 is lacking. Although both the AAP and CDC recommend testing all infants born to mothers with active SARS-CoV-2 infection at the time of delivery, the optimal strategy for evaluating vertical transmission in the setting of early (first- and second-trimester) pregnancy infections is not known. Although nasopharyngeal PCR-based testing of infants born to convalescent women is likely to be low yield, sampling the fetal compartment during maternal SARS-CoV-2 infection to assess for transmission could incur risk without a clear benefit. Estimates of the incidence of vertical transmission that exclude untested newborns should be interpreted with caution, as untested newborns cannot demonstrate their presumed SARS-CoV-2–negative status. We assert that the appropriate denominator to estimate the incidence of vertical transmission includes all newborns of women with SARS-CoV-2 infection during pregnancy." @default.
• W3158436306 created "2021-05-10" @default.
• W3158436306 creator A5005129143 @default.
• W3158436306 creator A5006883581 @default.
• W3158436306 creator A5007604692 @default.
• W3158436306 creator A5026575790 @default.
• W3158436306 creator A5032069045 @default.
• W3158436306 creator A5042380319 @default.
• W3158436306 creator A5049592434 @default.
• W3158436306 creator A5052131280 @default.
• W3158436306 creator A5079444051 @default.
• W3158436306 creator A5080905135 @default.
• W3158436306 creator A5087678081 @default.
• W3158436306 date "2021-07-01" @default.
• W3158436306 modified "2023-10-10" @default.
• W3158436306 title "Vertical transmission of SARS-CoV-2: consider the denominator" @default.
• W3158436306 cites W3087457854 @default.
• W3158436306 cites W3095913547 @default.
• W3158436306 doi "https://doi.org/10.1016/j.ajogmf.2021.100386" @default.
• W3158436306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8081748" @default.
• W3158436306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33932627" @default.
• W3158436306 hasPublicationYear "2021" @default.
• W3158436306 type Work @default.
• W3158436306 sameAs 3158436306 @default.
• W3158436306 citedByCount "7" @default.
• W3158436306 countsByYear W31584363062021 @default.
• W3158436306 countsByYear W31584363062022 @default.
• W3158436306 countsByYear W31584363062023 @default.
• W3158436306 crossrefType "journal-article" @default.
• W3158436306 hasAuthorship W3158436306A5005129143 @default.
• W3158436306 hasAuthorship W3158436306A5006883581 @default.
• W3158436306 hasAuthorship W3158436306A5007604692 @default.
• W3158436306 hasAuthorship W3158436306A5026575790 @default.
• W3158436306 hasAuthorship W3158436306A5032069045 @default.
• W3158436306 hasAuthorship W3158436306A5042380319 @default.
• W3158436306 hasAuthorship W3158436306A5049592434 @default.
• W3158436306 hasAuthorship W3158436306A5052131280 @default.
• W3158436306 hasAuthorship W3158436306A5079444051 @default.
• W3158436306 hasAuthorship W3158436306A5080905135 @default.
• W3158436306 hasAuthorship W3158436306A5087678081 @default.
• W3158436306 hasBestOaLocation W31584363061 @default.
• W3158436306 hasConcept C116675565 @default.
• W3158436306 hasConcept C126322002 @default.
• W3158436306 hasConcept C159047783 @default.
• W3158436306 hasConcept C2779134260 @default.
• W3158436306 hasConcept C2908974078 @default.
• W3158436306 hasConcept C3006700255 @default.
• W3158436306 hasConcept C3007834351 @default.
• W3158436306 hasConcept C3008058167 @default.
• W3158436306 hasConcept C3020799909 @default.
• W3158436306 hasConcept C39432304 @default.
• W3158436306 hasConcept C41008148 @default.
• W3158436306 hasConcept C524204448 @default.
• W3158436306 hasConcept C71924100 @default.
• W3158436306 hasConcept C761482 @default.
• W3158436306 hasConcept C76155785 @default.
• W3158436306 hasConceptScore W3158436306C116675565 @default.
• W3158436306 hasConceptScore W3158436306C126322002 @default.
• W3158436306 hasConceptScore W3158436306C159047783 @default.
• W3158436306 hasConceptScore W3158436306C2779134260 @default.
• W3158436306 hasConceptScore W3158436306C2908974078 @default.
• W3158436306 hasConceptScore W3158436306C3006700255 @default.
• W3158436306 hasConceptScore W3158436306C3007834351 @default.
• W3158436306 hasConceptScore W3158436306C3008058167 @default.
• W3158436306 hasConceptScore W3158436306C3020799909 @default.
• W3158436306 hasConceptScore W3158436306C39432304 @default.
• W3158436306 hasConceptScore W3158436306C41008148 @default.
• W3158436306 hasConceptScore W3158436306C524204448 @default.
• W3158436306 hasConceptScore W3158436306C71924100 @default.
• W3158436306 hasConceptScore W3158436306C761482 @default.
• W3158436306 hasConceptScore W3158436306C76155785 @default.
• W3158436306 hasFunder F4320337338 @default.
• W3158436306 hasFunder F4320337472 @default.
• W3158436306 hasFunder F4320337611 @default.
• W3158436306 hasIssue "4" @default.
• W3158436306 hasLocation W31584363061 @default.
• W3158436306 hasLocation W31584363062 @default.
• W3158436306 hasLocation W31584363063 @default.
• W3158436306 hasOpenAccess W3158436306 @default.
• W3158436306 hasPrimaryLocation W31584363061 @default.
• W3158436306 hasRelatedWork W3015777742 @default.
• W3158436306 hasRelatedWork W3022409537 @default.
• W3158436306 hasRelatedWork W3024980608 @default.
• W3158436306 hasRelatedWork W3087090141 @default.
• W3158436306 hasRelatedWork W3113664224 @default.
• W3158436306 hasRelatedWork W3165952552 @default.
• W3158436306 hasRelatedWork W3198020773 @default.
• W3158436306 hasRelatedWork W3209591042 @default.
• W3158436306 hasRelatedWork W4200329650 @default.
• W3158436306 hasRelatedWork W4289131272 @default.
• W3158436306 hasVolume "3" @default.
• W3158436306 isParatext "false" @default.
• W3158436306 isRetracted "false" @default.
• W3158436306 magId "3158436306" @default.
• W3158436306 workType "article" @default.